News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lux Biosciences Granted Fast Track Designation for LX201 for Corneal Transplant Rejection



1/30/2008 8:58:52 AM

JERSEY CITY, N.J.--(BUSINESS WIRE)--Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LX201, a silicone matrix ocular (episcleral) implant that steadily releases therapeutic doses of cyclosporine A locally to the eye to prevent corneal transplant rejection. LX201 is currently being tested in the one-year pivotal LUCIDA clinical trial program, comprising two controlled studies investigating the use of LX201 in patients at elevated immune-mediated risk of rejection or graft loss subsequent to cornea transplantation.

Read at press release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES